Old drug, new hope: enasidenib may ease anemia in blood cancer patients
NCT ID NCT05282459
First seen Apr 20, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tested whether enasidenib, a drug typically used for a different genetic type of leukemia, could safely improve anemia and reduce the need for blood transfusions in 17 people with lower-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who do not have an IDH2 mutation. Participants took enasidenib daily, and researchers measured changes in hemoglobin levels and transfusion needs over several months. The goal was to find a new treatment option for anemia in these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford Cancer Institute
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.